The drug most commonly associated with calvarial thickening is phenytoin. 1, 2 The pathological mechanism of action has been suggested to be upregulation of transforming growth factor-beta1 and bone morphogenic proteins, which in turn increase osteoblast proliferation. 3 Our patient confi rmed that he had never been given phenytoin. However, he demonstrated the same radiological features typical for chronic phenytoin use. Other possible causes of calvarial thickening, e.g. osteopetrosis, acromegaly, and hyperparathyroidism, were not present in our patient. Calvarial thickening is generally a benign condition, apart from cosmetic issues, and does not seem to have much clinical signifi cance. Some studies have suggested it can infl uence the estimation of brain atrophy especially in older women. 4 The average skull thickness in males is up to 6.5 mm and females up to 7 mm. One study suggested that the difference between male and female skulls was more towards the rear of the parietal bones. The mean thickness of the skull across all locations was 6.32 mm. It ranged from 5.3 mm to 7.5 mm. 5 The radiological fi ndings on the CT head of our patient leads us to consider whether there are other anti-epileptic drugs that may result in long term phenytoin-like changes in the form of calvarial thickening. Further research into this area and reporting of similar cases might help to establish such a link.
